osteolabs GmbH Successfully Closes Second Financing Round of Nearly 1.6 Million EUR

RAYUS Radiology Quality Institute Distinguished Nationally by Centers for Medicare & Medicaid

Quality Institute Again Earns Certification as Provider-Led Entity for Advanced Diagnostic Imaging Guidance to Clinicians.

LX1550 Multiparameter Remote Monitoring Platform Receives FDA 510 (k) Approval: Reports LifeSignals

Further validation of ability to deliver continuous remote patient vital signs monitoring within both hospital and home settings.

U.S. News & World Report Names Tampa General Hospital as Best in Tampa Bay

This is the sixth consecutive year that Tampa General has been named by U.S. News & World Report as Tampa Bay's top hospital.

December 8, 2020

osteolabs GmbH said the funds were provided by Seed and Start-Up Fonds II of MBG (Mittelständische Beteiligungsgesellschaft) Kiel, Labor Dr. Krause & Kollegen MVZ GmbH, Kiel, and SVM Verwaltungsgesellschaft mbH, Hamburg, as new shareholders.

On the one hand, the funds raised will be used to promote the further geographical expansion of osteolabs GmbH in the Scandinavian countries, the BENELUX countries, Switzerland and Austria. On the other hand, the capital will be used to further expand the existing laboratory capacities.

Dr. Bernd Buchholz, Minister of Economic Affairs of the Federal State of Schleswig-Holstein, summarised: “osteolabs is a good example of a successful and innovative start-up which has been successful to date and which the state is supporting with its financing instruments in a tailor-made way on the road to economic implementation and further development. This makes osteolabs one of a total of 67 companies that have so far been actively supported on their way into the market by the Schleswig-Holstein Seed and Start-up Fund II”.

Lucas Murmann, the investment manager of SVM, explains: “We have invested in this innovative biotech company because we are convinced that the OsteoTest procedure offers significant added value for patients and doctors in the treatment of osteoporosis. This disruptive procedure has a great market potential worldwide and we want to support its market penetration”.

“Since the company was founded, we are experiencing a continuous increase in orders, both from end customers and from medical practices,” says Managing Director Dr. Stefan Kloth happily. “This shows us that we are on the right track. After the successful roll-out in pharmacies throughout Germany, the OsteoTest is now also available to end consumers and can therefore be purchased not only online but also on-site”.

The innovative, CE-marked OsteoTest is protected by patent and has been clinically validated in several studies. It can be used both to detect osteoporosis and to monitor therapy. Up to now, patients have had to be exposed to X-rays for a diagnosis – in most cases when osteoporosis has already occurred.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.